Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor ofhuman neutrophilelastase(hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF)^[1][2][3].

Lonodelestat (POL6014) significantly and efficiently reduced the inflammatory processes of ALI in HNE treated mice^[1].
Lonodelestat (POL6014, 0.1, 0.5, 2 and 10 mg/kg, intranasally administered) dose-dependently and significantly reduces the number of macrophages, epithelial cells, neutrophils and lymphocytes recovered in BAL. The maximum inhibition was reached at 2 mg/kg in reducing neutrophils by 65% (p<0.001), epithelial cells by 68% (p<0.001), macrophages by 33% (p<0.001) and lymphocytes by 77% (p<0.001)^[1].

1592.75

C₇₃H₁₁₂F₃N₁₅O₂₁

cyclo[ASIPPQKYPPNle(bu)ET]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.